RedHill Biopharma: Eyes near 2-yr high as bowel disease drug meets main goals
30/07/2018 13:09
** U.S. shares of Israel-based drugmaker RDHL.O jump 31
pct to $12.33 before the opening bell; If gains hold, stock set
to open at highest since Nov 2016
** Shares among top pct gainers across U.S. exchanges
** Says a late-stage study of drug RHB-104 met main goals to
treat bowel disease Crohn's urn:newsml:reuters.com:*:nGNXbQJ1kQ
** RDHL says ~1.5 mln people globally had been diagnosed
with Crohn's disease as of 2017 and global sales of Crohn's
disease drugs are estimated to exceed $10 bln in 2018
** As of Friday's close, RDHL shares had nearly doubled in
value this year
(Reporting by Shreyashi Sanyal in Bengaluru)
((RM: Shreyashi.Sanyal.thomsonreuters.com@reuters.net))